Last reviewed · How we verify

Caudal dexamethasone

Kasr El Aini Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Caudal dexamethasone is a Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved. Also known as: Decadrone.

Caudal dexamethasone is a small molecule used in medical research, specifically studied for its analgesic effect in neonates undergoing inguinal hernia repair. It is administered via a caudal nerve block, which is a type of regional anesthesia.

At a glance

Generic nameCaudal dexamethasone
Also known asDecadrone
SponsorKasr El Aini Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Caudal dexamethasone

What is Caudal dexamethasone?

Caudal dexamethasone is a Small molecule drug developed by Kasr El Aini Hospital.

Who makes Caudal dexamethasone?

Caudal dexamethasone is developed and marketed by Kasr El Aini Hospital (see full Kasr El Aini Hospital pipeline at /company/kasr-el-aini-hospital).

Is Caudal dexamethasone also known as anything else?

Caudal dexamethasone is also known as Decadrone.

What development phase is Caudal dexamethasone in?

Caudal dexamethasone is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing